0001209191-13-040980.txt : 20130815
0001209191-13-040980.hdr.sgml : 20130815
20130815181322
ACCESSION NUMBER: 0001209191-13-040980
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20130813
FILED AS OF DATE: 20130815
DATE AS OF CHANGE: 20130815
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ONCOGENEX PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000949858
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 954343413
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1522 217TH PLACE S.E.
CITY: BOTHELL
STATE: WA
ZIP: 98021
BUSINESS PHONE: 4254879500
MAIL ADDRESS:
STREET 1: 1522 217TH PLACE S.E.
CITY: BOTHELL
STATE: WA
ZIP: 98021
FORMER COMPANY:
FORMER CONFORMED NAME: SONUS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19950825
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wyrick Susan D.
CENTRAL INDEX KEY: 0001568605
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 033-80623
FILM NUMBER: 131043392
MAIL ADDRESS:
STREET 1: 1522 217TH PLACE SE
STREET 2: SUITE 100
CITY: BOTHELL
STATE: WA
ZIP: 98021
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2013-08-13
0
0000949858
ONCOGENEX PHARMACEUTICALS, INC.
OGXI
0001568605
Wyrick Susan D.
1522 217TH PLACE SE
SUITE 100
BOTHELL
WA
98021
0
1
0
0
PAO
Common Stock
2013-08-13
4
M
0
1363
0.00
A
1363
D
Common Stock
2013-08-13
4
F
0
372
0.00
D
991
D
Restricted Stock Unit (RSU)
2013-08-13
4
M
0
688
0.00
D
2016-07-29
Common Stock
688
2062
D
Restricted Stock Unit (RSU)
2013-08-13
4
M
0
675
0.00
D
2014-04-30
Common Stock
675
1672
D
Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II.
Represents shares of common stock that have been withheld by the issuer to satisfy the income tax withholding and remittance obligations in connection with the net settlement of the RSUs, based on the close price of $9.32 per share on August 12, 2013.
Each RSU represents a contingent right to receive one share of the issuer's common stock at settlement.
Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest on August 13, 2013 and then annually on the later of: (i) each anniversary of June 29, 2012; and (ii) the first day thereafter during which the issuer's trading window is open.
Pursuant to the terms of the RSU, 100% of the total shares underlying the RSU vest on the later of (i) achievement of both the successful enrollment and release of data from certain clincial trails, and (ii) the first trading day thereafter on which the issuer's trading window is open, although less than 100% of the total shares may vest upon the achievement of certain, but not all, of the milestones.
Sandra Thomson as attorney-in-fact for Susan Wyrick
2013-08-15